featured
Gastroesophageal Adenocarcinoma Not Improved With Rilotumumab and Panitumumab
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
European Journal of Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
FOLFOX Alone or Combined With Rilotumumab or Panitumumab as First-Line Treatment for Patients With Advanced Gastroesophageal Adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): A Randomised, Open-Label, Three-Arm Phase II Trial
Eur. J. Cancer 2019 May 23;115(xx)97-106, D Malka, E François, F Penault-Llorca, F Castan, O Bouché, J Bennouna, F Ghiringhelli, C Fouchardière, C Borg, E Samalin, JB Bachet, JL Raoul, L Miglianico, L Bengrine-Lefèvre, L Dahan, C Lecaille, T Aparicio, T Stanbury, H Perrier, A Cayre, P Laurent-Puig, S Gourgou, JF Emile, J TaïebFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.